[The human hematopoietic stem cell, normal and leukemic]

Same author

A microRNA code for prostate cancer metastasis.

Oncogene·2015

Same author

IL-2 induces the release of secondary cytokines which stimulate the cytotoxic activity of either NK or CD8(+) lymphocytes.

Cytotechnology·2012

Same author

Long-term culture of human LAK cells.

Cytotechnology·2012

Same author

A transcriptome-wide approach reveals the key contribution of NFI-A in promoting erythroid differentiation of human CD34(+) progenitors and CML cells.

Leukemia·2010

Same author

The interplay between the master transcription factor PU.1 and miR-424 regulates human monocyte/macrophage differentiation.

Proceedings of the National Academy of Sciences of the United States of America·2007

Same author

Identification and expansion of the tumorigenic lung cancer stem cell population.

Cell death and differentiation·2007

Same journal

Emapalumab and eltrombopag rescue for prolonged immune effector cell-associated hemophagocytic syndrome after CAR T-cell therapy in multiple myeloma.

Haematologica·2026

Same journal

Incidence and predictors of recurrent venous thromboembolism after isolated distal deep vein thrombosis: a <i>post-hoc</i> analysis of the RIDTS trial.

Haematologica·2026

Same journal

Philadelphia positive T-acute lymphoblastic leukemia: a Mayo Clinic series.

Haematologica·2026

Same journal

Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia.

Haematologica·2026

Same journal

Reframing leukemia-niche interactions: the emerging role of the marrow adipocyte lineage.

Haematologica·2026

Same journal

A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma.

Haematologica·2026

Related Experiment Videos

[The human hematopoietic stem cell, normal and leukemic]

Related Concept Videos

A microRNA code for prostate cancer metastasis.

IL-2 induces the release of secondary cytokines which stimulate the cytotoxic activity of either NK or CD8(+) lymphocytes.

Long-term culture of human LAK cells.

A transcriptome-wide approach reveals the key contribution of NFI-A in promoting erythroid differentiation of human CD34(+) progenitors and CML cells.

The interplay between the master transcription factor PU.1 and miR-424 regulates human monocyte/macrophage differentiation.

Identification and expansion of the tumorigenic lung cancer stem cell population.

Emapalumab and eltrombopag rescue for prolonged immune effector cell-associated hemophagocytic syndrome after CAR T-cell therapy in multiple myeloma.

Incidence and predictors of recurrent venous thromboembolism after isolated distal deep vein thrombosis: a <i>post-hoc</i> analysis of the RIDTS trial.

Philadelphia positive T-acute lymphoblastic leukemia: a Mayo Clinic series.

Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia.

Reframing leukemia-niche interactions: the emerging role of the marrow adipocyte lineage.

A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma.

Related Experiment Videos

[The human hematopoietic stem cell, normal and leukemic]

Related Concept Videos

Related Articles

A microRNA code for prostate cancer metastasis.

IL-2 induces the release of secondary cytokines which stimulate the cytotoxic activity of either NK or CD8(+) lymphocytes.

Long-term culture of human LAK cells.

A transcriptome-wide approach reveals the key contribution of NFI-A in promoting erythroid differentiation of human CD34(+) progenitors and CML cells.

The interplay between the master transcription factor PU.1 and miR-424 regulates human monocyte/macrophage differentiation.

Identification and expansion of the tumorigenic lung cancer stem cell population.

Emapalumab and eltrombopag rescue for prolonged immune effector cell-associated hemophagocytic syndrome after CAR T-cell therapy in multiple myeloma.

Incidence and predictors of recurrent venous thromboembolism after isolated distal deep vein thrombosis: a <i>post-hoc</i> analysis of the RIDTS trial.

Philadelphia positive T-acute lymphoblastic leukemia: a Mayo Clinic series.

Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia.

Reframing leukemia-niche interactions: the emerging role of the marrow adipocyte lineage.

A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma.